(Q73801777)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

M T Vlachaki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

C S Ha

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

F B Hagemeister

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

L M Fuller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

M A Rodriguez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

P C Besa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

M A Hess

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

B Brown

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

J D Cox

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 October 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Radiation Oncology Biology Physics

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

609-616

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Coronary artery disease mortality in patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: Evidence of a more difficult rescue for patients relapsed after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Pericarditis and myocardial infarctions after Hodgkin's disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Clinical versus pathologic stage I and II Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Radiation therapy in clinical stage I and II Hodgkin's disease. The Princess Margaret Hospital Lymphoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Late relapse among patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Progress in the treatment of Hodgkin's disease in the United States, 1973 versus 1983. The Patterns of Care Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Female Reproductive Potential after Treatment for Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Hodgkin's disease limited to intrathoracic sites

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

The role of radiation therapy in Hodgkin disease: experience and controversy. The 54th annual Janeway Lecture: 1989.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Radical treatment of Hodgkin disease with radiation therapy: results of a 15-year clinical trial. The 1985 Erskine lecture.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

The role of prognostic factors in treatment selection for early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

The impact of stage and treatment modality on the likelihood of second malignancies and hematopoietic disorders in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Hodgkin's disease: study of treatment intensities and incidences of second malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Risk of second cancers after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

An updated dose-response analysis in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900371-4

7 January 2021

10.1016/S0360-3016(97)00371-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9336140%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference